BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verza FA, Das U, Fachin AL, Dimmock JR, Marins M. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. Cancers (Basel) 2020;12:E1664. [PMID: 32585896 DOI: 10.3390/cancers12061664] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Lisi S, Trovato M, Vitaloni O, Fantini M, Chirichella M, Tognini P, Cornuti S, Costa M, Groth M, Cattaneo A. Acetylation-Specific Interference by Anti-Histone H3K9ac Intrabody Results in Precise Modulation of Gene Expression. IJMS 2022;23:8892. [DOI: 10.3390/ijms23168892] [Reference Citation Analysis]
2 Xu Y, Tang H, Xu Y, Guo J, Zhao X, Meng Q, Xiao J. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors. Molecules 2022;27:3335. [DOI: 10.3390/molecules27103335] [Reference Citation Analysis]
3 Lanzi C, Cassinelli G. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas. Biochemical Pharmacology 2022;198:114944. [DOI: 10.1016/j.bcp.2022.114944] [Reference Citation Analysis]
4 Mayer M, Berger A, Leischner C, Renner O, Burkard M, Böcker A, Noor S, Weiland T, Weiss TS, Busch C, Lauer UM, Bischoff SC, Venturelli S. Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma. Pharmaceuticals 2022;15:438. [DOI: 10.3390/ph15040438] [Reference Citation Analysis]
5 Xu Y, Liao W, Luo Q, Yang D, Pan M. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol 2022;13:761046. [DOI: 10.3389/fimmu.2022.761046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yan X, Kang D, Lin Y, Qi S, Jiang C. CBX4-dependent regulation of HDAC3 nuclear translocation reduces Bmp2-induced osteoblastic differentiation and calcification in adamantinomatous craniopharyngioma. Cell Commun Signal 2022;20:3. [PMID: 34980138 DOI: 10.1186/s12964-021-00797-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Rashidbaghan A, Mostafaie A, Yazdani Y; Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran., Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran., Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran. More Related Gene Pathways to Vincristine-Induced Death Events in a Human T-Acute Lymphoblastic Leukemia Cell Line. rbmb net 2022;10:554-64. [DOI: 10.52547/rbmb.10.4.554] [Reference Citation Analysis]
8 Li Y, Sang S, Ren W, Pei Y, Bian Y, Chen Y, Sun H. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020). Eur J Med Chem 2021;226:113874. [PMID: 34619465 DOI: 10.1016/j.ejmech.2021.113874] [Reference Citation Analysis]
9 Wang S, Song M, Zhang B. Trichostatin A enhances radiosensitivity and radiation-induced DNA damage of esophageal cancer cells. J Gastrointest Oncol 2021;12:1985-95. [PMID: 34790366 DOI: 10.21037/jgo-21-560] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Samuelov L, Bochner R, Magal L, Malovitski K, Sagiv N, Nousbeck J, Keren A, Fuchs-Telem D, Sarig O, Gilhar A, Sprecher E. Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis. Exp Dermatol 2021. [PMID: 34787924 DOI: 10.1111/exd.14502] [Reference Citation Analysis]
11 Sokolov AV, Dostdar SA, Attwood MM, Krasilnikova AA, Ilina AA, Nabieva AS, Lisitsyna AA, Chubarev VN, Tarasov VV, Schiöth HB. Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies. Pharmacol Rev 2021;73:1-32. [PMID: 34663683 DOI: 10.1124/pharmrev.121.000317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Gupta S, Ahmed MM. Targeting radiation-induced upstream stimulatory factor-1 by histone deacetylase inhibitors to reverse radioresistance in prostate cancer. Cancer Rep (Hoboken) 2021;:e1553. [PMID: 34533293 DOI: 10.1002/cnr2.1553] [Reference Citation Analysis]
13 Li F, Wang D, Wang H, Chen L, Sun X, Wan Y. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a. Respir Res 2021;22:239. [PMID: 34465322 DOI: 10.1186/s12931-021-01832-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Ekronarongchai S, Palaga T, Saonanon P, Pruksakorn V, Hirankarn N, van Hagen PM, Dik WA, Virakul S. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients. Thyroid 2021. [PMID: 34235979 DOI: 10.1089/thy.2020.0948] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 2021;14:121. [PMID: 34372899 DOI: 10.1186/s13045-021-01111-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ikeda Y, Nagase N, Tsuji A, Taniguchi K, Kitagishi Y, Matsuda S. Comprehension of the Relationship between Autophagy and Reactive Oxygen Species for Superior Cancer Therapy with Histone Deacetylase Inhibitors. Oxygen 2021;1:22-31. [DOI: 10.3390/oxygen1010004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lu X, Yan G, Dawood M, Klauck SM, Sugimoto Y, Klinger A, Fleischer E, Shan L, Efferth T. A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells. Biochem Pharmacol 2021;:114677. [PMID: 34265280 DOI: 10.1016/j.bcp.2021.114677] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
18 Chen L, Fei Y, Zhao Y, Chen Q, Chen P, Pan L. Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis. Medicine (Baltimore) 2021;100:e26554. [PMID: 34232196 DOI: 10.1097/MD.0000000000026554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Yang H, Sun B, Xu K, He Y, Zhang T, Hall SRR, Tan ST, Schmid RA, Peng RW, Hu G, Yao F. Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. EBioMedicine 2021;69:103457. [PMID: 34224975 DOI: 10.1016/j.ebiom.2021.103457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kasprzyk ME, Sura W, Dzikiewicz-Krawczyk A. Enhancing B-Cell Malignancies-On Repurposing Enhancer Activity towards Cancer. Cancers (Basel) 2021;13:3270. [PMID: 34210001 DOI: 10.3390/cancers13133270] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Michalkova R, Mirossay L, Gazdova M, Kello M, Mojzis J. Molecular Mechanisms of Antiproliferative Effects of Natural Chalcones. Cancers (Basel) 2021;13:2730. [PMID: 34073042 DOI: 10.3390/cancers13112730] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
23 Hayes AJ, Melrose J. What Are the Potential Roles of Nuclear Perlecan and Other Heparan Sulphate Proteoglycans in the Normal and Malignant Phenotype. Int J Mol Sci 2021;22:4415. [PMID: 33922532 DOI: 10.3390/ijms22094415] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 Zhang XH, Kang HQ, Tao YY, Li YH, Zhao JR, Ya-Gao, Ma LY, Liu HM. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. Eur J Med Chem 2021;218:113392. [PMID: 33831778 DOI: 10.1016/j.ejmech.2021.113392] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
25 Martín-Bernabé A, Tarragó-Celada J, Cunin V, Michelland S, Cortés R, Poignant J, Boyault C, Rachidi W, Bourgoin-Voillard S, Cascante M, Seve M. Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia. Int J Mol Sci 2021;22:3378. [PMID: 33806075 DOI: 10.3390/ijms22073378] [Reference Citation Analysis]
26 Lüdtke TH, Wojahn I, Kleppa MJ, Schierstaedt J, Christoffels VM, Künzler P, Kispert A. Combined genomic and proteomic approaches reveal DNA binding sites and interaction partners of TBX2 in the developing lung. Respir Res 2021;22:85. [PMID: 33731112 DOI: 10.1186/s12931-021-01679-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Rahmani G, Sameri S, Abbasi N, Abdi M, Najafi R. The clinical significance of histone deacetylase-8 in human breast cancer. Pathol Res Pract 2021;220:153396. [PMID: 33691240 DOI: 10.1016/j.prp.2021.153396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Cozzolino F, Iacobucci I, Monaco V, Angrisano T, Monti M. Lysines Acetylome and Methylome Profiling of H3 and H4 Histones in Trichostatin A-Treated Stem Cells. Int J Mol Sci 2021;22:2063. [PMID: 33669725 DOI: 10.3390/ijms22042063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Oleksiewicz U, Machnik M. Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. Semin Cancer Biol 2020:S1044-579X(20)30274-1. [PMID: 33359485 DOI: 10.1016/j.semcancer.2020.12.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
30 Naveen Sadhu M, Sivanandhan D, Gajendran C, Tantry S, Dewang P, Murugan K, Chickamunivenkatappa S, Zainuddin M, Nair S, Vaithilingam K, Rajagopal S. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma. Bioorg Med Chem Lett 2021;34:127763. [PMID: 33359604 DOI: 10.1016/j.bmcl.2020.127763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Luo Y, Li H. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). Int J Mol Sci 2020;21:E8828. [PMID: 33266366 DOI: 10.3390/ijms21228828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Benassi A, Doria F, Pirota V. Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds. Int J Mol Sci 2020;21:E8692. [PMID: 33217987 DOI: 10.3390/ijms21228692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
33 Ranganna K, Selvam C, Shivachar A, Yousefipour Z. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. Int J Mol Sci 2020;21:E8198. [PMID: 33147762 DOI: 10.3390/ijms21218198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
34 Peters GJ, van Gemert FPA, Kathmann I, Reddy G, Cillessen SAGM, Jansen G. Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro. Front Cell Dev Biol 2020;8:577215. [PMID: 33163492 DOI: 10.3389/fcell.2020.577215] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Wiesel-Motiuk N, Assaraf YG. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology. Drug Resist Updat 2020;53:100729. [PMID: 33130515 DOI: 10.1016/j.drup.2020.100729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
36 Chen J, Zhou J, Fu H, Ni X, Shan Y. Upregulation of oxidative stress-responsive 1(OXSR1) predicts poor prognosis and promotes hepatocellular carcinoma progression. Bioengineered 2020;11:958-71. [PMID: 32842855 DOI: 10.1080/21655979.2020.1814659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kuykendall AT, Horvat NP, Pandey G, Komrokji R, Reuther GW. Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers (Basel) 2020;12:E2278. [PMID: 32823910 DOI: 10.3390/cancers12082278] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]